Core Viewpoint - The company has initiated a Phase I clinical trial for its self-developed candidate drug HX111, an OX40-targeted antibody-drug conjugate (ADC), aimed at treating relapsed/refractory lymphoma and solid tumors, with the first patient successfully dosed recently [1] Group 1: Drug Development - HX111 is designed to bind with high affinity and specificity to the OX40 molecule on the surface of tumor cells, facilitating efficient internalization and subsequent release of a potent payload that induces tumor cell apoptosis [1] - The OX40 molecule is highly expressed in certain lymphomas and solid tumors, which currently lack effective treatment options, indicating a significant unmet clinical need [1] - HX111 is the first OX40-targeted ADC drug to enter clinical trials globally, representing a first-in-class (FIC) innovation in this therapeutic area [1] Group 2: Market Opportunity - The field of OX40-targeted therapies is still in the early exploratory stage, providing HX111 with a significant first-mover advantage [1] - The development of HX111 has the potential to address a critical gap in the treatment landscape for these types of tumors [1]
翰思艾泰-B：HX111完成首例病人用药